Faeth Therapeutics, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Faeth Therapeutics, Inc. (FTH) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$186.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-04
- Faeth Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$16.01M.
- Faeth Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$170.24M.
- Faeth Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$4.72M.
- Faeth Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$4.57M.
- Faeth Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$21.09M.
- Faeth Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$30.16M.
- Faeth Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$34.10M.
- Faeth Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$48.59M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$16.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$186.24M 10-Q · filed 2026-08-04 | -$190.96M derived: sum of 3 quarters · filed 2026-08-04 | -$195.53M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$170.24M 10-Q · filed 2026-05-15 | -$174.95M derived: sum of 2 quarters · filed 2026-05-15 | -$179.52M derived: sum of 3 quarters · filed 2026-05-15 | -$184.46M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$4.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$9.29M derived: sum of 2 quarters · filed 2026-03-30 | -$14.22M derived: sum of 3 quarters · filed 2026-08-04 | -$21.09M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$4.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$9.50M derived: sum of 2 quarters · filed 2026-08-04 | -$16.37M 10-Q · filed 2025-11-14 | -$24.14M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$4.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$11.80M 10-Q · filed 2026-08-04 | -$19.57M derived: sum of 3 quarters · filed 2026-08-04 | -$26.82M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$6.86M 10-Q · filed 2026-05-15 | -$14.63M derived: sum of 2 quarters · filed 2026-05-15 | -$21.89M derived: sum of 3 quarters · filed 2026-05-15 | -$29.03M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$7.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$15.02M derived: sum of 2 quarters · filed 2026-03-30 | -$22.16M derived: sum of 3 quarters · filed 2026-03-30 | -$30.16M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$7.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$14.39M derived: sum of 2 quarters · filed 2025-11-14 | -$22.39M 10-Q · filed 2025-11-14 | -$29.80M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$7.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$15.13M 10-Q · filed 2025-08-05 | -$22.55M derived: sum of 3 quarters · filed 2025-08-05 | -$29.67M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$7.99M 10-Q · filed 2025-05-06 | -$15.41M derived: sum of 2 quarters · filed 2025-05-06 | -$22.53M derived: sum of 3 quarters · filed 2025-05-06 | -$31.92M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$7.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$14.54M derived: sum of 2 quarters · filed 2025-03-28 | -$23.92M derived: sum of 3 quarters · filed 2025-03-28 | -$34.10M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$7.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$16.51M derived: sum of 2 quarters · filed 2024-11-14 | -$26.69M 10-Q · filed 2024-11-14 | -$38.92M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$9.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$19.56M 10-Q · filed 2024-08-06 | -$31.80M derived: sum of 3 quarters · filed 2024-08-06 | -$45.21M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$10.18M 10-Q · filed 2024-05-09 | -$22.41M derived: sum of 2 quarters · filed 2024-05-09 | -$35.83M derived: sum of 3 quarters · filed 2024-05-09 | -$46.36M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$12.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$25.65M derived: sum of 2 quarters · filed 2024-02-29 | -$36.18M derived: sum of 3 quarters · filed 2024-02-29 | -$48.59M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$13.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$23.95M derived: sum of 2 quarters · filed 2023-11-07 | -$36.36M 10-Q · filed 2023-11-07 | -$45.72M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$10.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$22.94M 10-Q · filed 2023-08-03 | -$32.31M derived: sum of 3 quarters · filed 2023-08-03 | -$41.99M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$12.40M 10-Q · filed 2023-05-09 | -$21.77M derived: sum of 2 quarters · filed 2023-05-09 | -$31.46M derived: sum of 3 quarters · filed 2023-05-09 | -$41.23M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$9.37M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$19.05M derived: sum of 2 quarters · filed 2023-03-29 | -$28.82M derived: sum of 3 quarters · filed 2023-03-29 | -$36.79M 10-K · filed 2023-03-29 |
| 2021-09-30 | -$9.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$19.46M derived: sum of 2 quarters · filed 2022-11-08 | -$27.43M 10-Q · filed 2022-11-08 | -$32.56M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$9.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$17.74M 10-Q · filed 2022-08-09 | -$22.87M derived: sum of 3 quarters · filed 2022-08-09 | -$28.24M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$7.97M 10-Q · filed 2022-05-10 | -$13.10M derived: sum of 2 quarters · filed 2022-05-10 | -$18.47M derived: sum of 3 quarters · filed 2022-05-10 | -$23.38M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$5.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$10.50M derived: sum of 2 quarters · filed 2022-03-15 | -$15.41M derived: sum of 3 quarters · filed 2022-03-15 | -$20.10M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$5.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$10.28M derived: sum of 2 quarters · filed 2021-11-10 | -$14.97M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$4.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$9.60M 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | -$4.69M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |